If you follow any longevity content online, you have heard the pitch: NAD+ is the fuel your cells run on, it drops as you age, and a supplement like NMN or NR can top it back up. The first two points are solid science. The third is where the hype outruns the evidence — many articles quietly swap impressive mouse data for thin human data and hope you do not notice. This piece does the opposite. We walked through the actual human clinical trials, one by one, to separate what has been shown in people from what has only been shown in rodents.
The underlying biology — why NAD+ falls with age, what CD38 has to do with it and what the decline does inside the cell — is covered in the sections further down this page. Here, we focus narrowly on one question: when real people swallow these supplements in controlled trials, what actually happens?
A quick primer: NAD+, NMN and NR
NAD+ (nicotinamide adenine dinucleotide) is a helper molecule every cell depends on to produce energy and repair DNA. Its levels genuinely decline with age across many tissues, which is why restoring it became such an attractive target. You cannot usefully swallow NAD+ itself — it is broken down before it reaches your cells — so the supplements on the market are precursors: smaller building blocks your body converts into NAD+. The two most studied are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside). Both have now been tested in genuine randomized, placebo-controlled human trials, which is more than can be said for most longevity supplements.
The core distinction: NAD+ is the destination, NMN is the delivery route
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every living cell. It carries electrons in the reactions that turn food into usable energy, and it is the fuel that sirtuins and PARP enzymes burn when they repair DNA and regulate how genes switch on and off.[9] When people say "NAD+ powers your cells," that is not marketing — it is basic biochemistry. The catch is that NAD+ levels decline measurably across many tissues as we age, which is why restoring it became such a popular target.[10]
NMN (nicotinamide mononucleotide) is not that working molecule. It is one step upstream: a precursor that your cells take in and convert into NAD+ through a short enzymatic pathway. Think of NAD+ as the finished currency your cells spend, and NMN as the raw metal it gets minted from. NR (nicotinamide riboside) is another precursor, one step further back again, that first becomes NMN and then NAD+. So the family tree runs NR to NMN to NAD+ — three related molecules, not three rival products.
So why not just take NAD+ directly?
This is the obvious question, and it has a clear answer: swallowing NAD+ itself does very little, because the intact molecule is large and unstable in the digestive tract. It is broken down before it can be absorbed and delivered to your cells in any meaningful quantity, which is exactly why the supplement industry settled on smaller, better-absorbed precursors instead. There is essentially no body of randomized human trials showing that oral NAD+ capsules raise cellular NAD+ the way NMN and NR demonstrably do. That absence of evidence is the whole reason precursors exist as products.
You may have seen NAD+ offered as an intravenous drip or an injection, which bypasses the gut entirely. That is a different delivery method, not a different molecule, and it comes with its own caveats: IV NAD+ is expensive, time-consuming, often uncomfortable during infusion, and the controlled evidence that it produces durable anti-aging benefits in healthy people is thin. For most people asking "NMN or NAD+," the practical reality is that an oral precursor is the only version with real human absorption data behind it.
Why NAD+ declines with age
Here is the fact that launched a thousand supplements: NAD+ levels fall as we get older. A review in Experimental Gerontology by McReynolds, Chellappa and Baur surveys the evidence that NAD+ concentrations decline in the tissues of aged animals and examines the candidate mechanisms — increased consumption, decreased synthesis, or shifts in the cellular makeup of tissues — while noting that direct human data remain limited and that better tools are still needed to pin down which tissues and compartments are most affected.[10] That last caveat matters: the decline is real, but it is more nuanced than the influencer version, in which NAD+ simply "runs out."
So why does it fall? The most compelling recent answer points less at a factory that stops making NAD+ and more at consumers who burn through it faster. According to PubMed, an isotope-tracing study in Cell Systems found that in aged mice, tissue NAD+ dropped modestly (a median decrease of roughly 30%), yet the rate of NAD+ production was largely maintained — the smaller pool simply turned over faster, consistent with more active NAD+-consuming enzymes; calorie restriction partly blunted the decline by reducing consumption.[11] This reframes the whole problem. If aging tissues are not failing to make NAD+ so much as spending it too fast, then the interesting target may be the spenders.
CD38: the NAD+ vacuum cleaner of an aging body
Among those spenders, one enzyme keeps coming up: CD38. It is an NAD+-consuming enzyme found largely on immune cells, and its activity rises with age — in step with the chronic, low-grade inflammation ("inflammaging") that accompanies getting older. A review in Mechanisms of Ageing and Development frames age-related NAD+ loss explicitly as a balance problem between biosynthesis and consumption, describing how reduced levels of the rate-limiting synthesis enzyme NAMPT combine with increased activation of the NAD+-consuming enzymes PARPs and CD38 to drain tissue NAD+ — and how restoring NAD+ can halt or reverse some age-related disease in models.[12] The picture that emerges is a tug-of-war: on one side, production machinery that slows a little; on the other, a growing crowd of NAD+ consumers — PARPs responding to accumulating DNA damage, and CD38 ramping up with age-related inflammation. NAD+ decline is the net result.
The sirtuins, PARPs and the DNA-repair connection
The sirtuins are the enzymes that made NAD+ famous in longevity circles. They strip chemical tags off proteins and DNA-packaging histones, and in doing so they help regulate metabolism, inflammation, mitochondrial biogenesis and the stress responses that keep cells healthy. The catch is that sirtuins cannot function without NAD+ — it is their obligatory cofactor. When NAD+ runs low, sirtuin activity falls with it, regardless of how many sirtuins the cell has.
The PARPs are the cell's DNA-damage first responders. When your genome takes a hit — and it takes thousands of hits a day — PARP enzymes rush in and consume large amounts of NAD+ to flag and coordinate the repair. This sets up a quiet competition: every time PARPs fire to fix DNA, they are spending the same NAD+ that sirtuins and mitochondria need. According to PubMed, a review of neurodegeneration in accelerated-aging disorders details exactly this dynamic, showing how nuclear DNA damage drives PARP1 hyperactivation, which depletes NAD+ and downstream metabolites and impairs mitochondrial function — and how restoring those metabolites can reverse some of the damage in models.[13] That is the mechanistic heart of why people care about NAD+: it sits at the intersection of energy, repair and the enzymes that govern healthy aging.
What the decline does to cells
Follow the chain and the downstream consequences become intuitive. Less NAD+ means mitochondria have less of the shuttle they need to run oxidative metabolism efficiently — energy production gets less crisp. Less NAD+ means sirtuins, which depend on it, work less, loosening the regulation of metabolism, inflammation and mitochondrial upkeep. Less NAD+ means PARPs have less fuel to coordinate DNA repair even as damage accumulates. None of these failures is dramatic on its own; together, over decades, they map neatly onto the hallmarks of cellular aging — mitochondrial dysfunction, genomic instability, senescence and chronic inflammation — which is precisely why NAD+ has become such a magnet for longevity research.[9]
Step one is settled: these supplements do raise NAD+ in humans
The clearest, most consistent finding across the literature is that NMN and NR actually increase NAD+ in people — not just in mice. In a randomized, double-blind, placebo-controlled dose-ranging trial, 80 healthy middle-aged adults took placebo or 300, 600 or 900 mg of NMN daily for 60 days; blood NAD+ rose significantly in every NMN group, with the highest levels at 600 and 900 mg.[1] A separate Japanese trial gave 250 mg of NMN daily to healthy older men and confirmed the same thing using detailed metabolomic blood analysis.[2] On the NR side, a crossover trial in healthy middle-aged and older adults showed NR was well tolerated and effectively boosted NAD+ metabolism,[3] and a trial in aged men found that NR even raised the NAD+ metabolome inside skeletal muscle tissue, not just the bloodstream.[4] So the foundational claim — "these pills raise the molecule that declines with age" — is real and reproducible in humans.
The comparison that actually matters: NMN vs NR
Once you accept that a precursor is the sensible route, the genuine decision is NMN versus NR — the two precursors that have actually been tested in randomized, placebo-controlled human trials. Here is how they line up.
| NMN | NR | |
|---|---|---|
| What it is | Direct precursor, one step from NAD+ | Precursor that converts to NMN first, then NAD+ |
| Raises NAD+ in humans? | Yes, confirmed in randomized trials[1] | Yes, confirmed in randomized trials[3] |
| Typical trial dose | 250 to 600 mg/day | 300 to 1000 mg/day |
| Regulatory status (US) | Contested by the FDA as a supplement ingredient | More settled; marketed as a supplement for years |
| Best single positive trial | Improved muscle insulin sensitivity in prediabetic women[8] | Well tolerated, raised NAD+; some cardiovascular signals[3] |
Step two is where it gets honest: the downstream benefits are mixed
Raising NAD+ is only interesting if it translates into something you would notice. Here the picture is far more cautious. The same 80-person NMN trial reported that walking distance on a six-minute walking test improved more in every NMN group than in placebo, with the longest distances in the 600 mg and 900 mg groups.[1] A six-week study in 48 recreationally trained amateur runners found that 600 and 1200 mg of NMN daily improved aerobic capacity markers during cycling tests, apparently by helping muscle use oxygen more efficiently.[5] The older-men NMN trial saw "nominally significant" improvements in gait speed and left-hand grip — the authors' own careful wording, flagging that these need confirmation in larger studies.[2]
For NR, a randomized crossover trial recorded a modest drop in systolic blood pressure and arterial stiffness over six weeks among participants who started with elevated readings — but that was an exploratory, non-significant signal, and the authors framed it only as something future trials should go on to test.[3] The muscle-tissue NR trial also detected an anti-inflammatory shift in the blood.[4] These are real signals, but every one of them is small, short-term and in need of replication.
The null results matter just as much
Honest reporting means showing the trials that found nothing. A rigorous 12-week trial gave obese, insulin-resistant men 1000 mg of NR twice daily and measured insulin sensitivity with the gold-standard hyperinsulinemic-euglycemic clamp. The result was clear: no improvement in insulin sensitivity, glucose metabolism, body composition or fat handling — though it was confirmed safe.[6] The big NMN dose-ranging trial likewise found no improvement in insulin resistance scores.[1] And a 2025 systematic review and meta-analysis that pooled the randomized trials of NMN and NR in older adults reached a sobering conclusion: the current evidence does not support these supplements for preserving muscle mass, grip strength or gait speed in people over 60.[7] When you combine the studies statistically, the small individual wins largely wash out.
The one human trial that arguably moved the metabolic needle is worth singling out because it was so carefully done: a 10-week, placebo-controlled study of 250 mg NMN daily in postmenopausal women with prediabetes who were overweight or obese. Using the same clamp gold standard, it found that NMN improved muscle insulin sensitivity and insulin signaling.[8] That is a genuinely positive, well-controlled result — but it was a single trial in a specific population, and it has not yet been replicated at scale.
Why the mouse studies look so much better than the human ones
It is worth pausing on why the gap between rodent and human results is so wide, because it is the single biggest reason longevity marketing feels more exciting than the trials justify. In mice, NAD+ precursors have been linked to improved insulin sensitivity, better endurance, healthier blood vessels and even modestly longer life in some strains. Those results are real — but mice are not small humans. Laboratory mice are genetically uniform, kept in controlled conditions, and often deliberately aged or made metabolically sick so that a treatment has obvious room to help. Their metabolism runs far faster than ours, and the doses used, scaled to body weight, are frequently much higher than what people take. A compound that rescues a stressed, NAD+-depleted mouse may do very little in a reasonably healthy adult whose NAD+ is only modestly lower than it was at twenty. This is the classic translational gap, and NAD+ boosters sit squarely inside it: the biology is plausible, the animal data are encouraging, and the human payoff has so far been small and inconsistent. None of that makes the supplements useless — it simply means the honest verdict is "promising and unproven," not "clinically proven."
Side effects and safety
The safety record in trials is reassuring, within its limits. Across the human studies done so far, NMN has been well tolerated at doses from roughly 250 to 900 mg per day, with no serious adverse effects attributed to it.[1][2] The most commonly mentioned nuisance effects are mild and infrequent: nausea, digestive upset, headache or flushing. For context, trials of the closely related precursor NR have also confirmed safety over months of daily use.[14]
The honest caveats are about time and regulation, not toxicity. The trials ran only weeks to months, so long-term safety is genuinely unknown. Because NMN influences NAD+ metabolism throughout the body, anyone who is pregnant or breastfeeding, has an active cancer, or takes prescription medication should talk to a doctor before starting. And in the United States the FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug — a regulatory dispute that does not change the science but does explain why availability, labeling and quality are inconsistent. That inconsistency is exactly why brand choice matters so much.
How to choose an NMN brand
With a loosely regulated ingredient, the product is the variable you control. Use this checklist.
- Third-party certificate of analysis (COA). This is non-negotiable. A reputable brand publishes an independent lab report confirming identity, purity (look for 98 to 99 percent or higher) and the absence of contaminants. No COA, no purchase.
- Stated milligrams of NMN, not a "proprietary blend." You want to see the actual dose per serving so you can match the trial range of 250 to 600 mg per day. Blends that hide the NMN amount behind other ingredients are a red flag.
- Cool, sealed, opaque packaging. NMN is sensitive to heat and moisture and can degrade, so look for sealed blister packs or well-sealed bottles, and store it cool. Some brands recommend refrigeration.
- Sensible price and claims. Genuine high-purity NMN is not the cheapest powder on the marketplace; unusually cheap products often are not what the label says. Equally, walk away from anything promising to "reverse aging" — no NMN product has evidence for that.
- Reasonable dose, not the biggest number. More is not clearly better. The human trials clustered at 250 to 600 mg per day, and the standout insulin result used just 250 mg. Start low.
One more practical point: if regulatory uncertainty around NMN bothers you, NR is a closely related precursor with a more settled legal status and its own supporting trials. We compare the two directly in NMN vs NAD+: which should you take.
How to read these trials without fooling yourself
A few habits help you judge NAD+ headlines for yourself. First, separate the biomarker from the outcome you actually care about: "raised NAD+" is a biomarker, while "walked farther," "lower blood pressure" or "better insulin sensitivity" are outcomes — and a supplement can move the first without reliably moving the second. Second, watch the sample size and duration. Several of the encouraging trials enrolled only a few dozen people for six to twelve weeks, which is enough to detect a biomarker shift but far too small and brief to prove a meaningful health benefit, let alone a longevity effect. Third, note primary versus secondary findings: the blood-pressure improvement in the NR trial and the walking gains in the NMN trials were secondary or exploratory measures, which carry more risk of being chance findings than a study's pre-specified main goal. Fourth, give extra weight to meta-analyses, which pool many trials and are harder to fool — and the most recent pooled analysis in older adults came up empty for muscle and physical performance.[7] Applying these filters, the literature stops looking like a string of breakthroughs and starts looking like what it is: an early, genuinely interesting field that has not yet delivered a clear human win beyond raising the molecule itself.
What about NMN's legal status?
There is also a regulatory wrinkle worth knowing. In the United States, the FDA's position on NMN as a dietary supplement has been contested: the agency has taken the view that NMN is excluded from the supplement definition because it has been investigated as a drug, which has created ongoing uncertainty for sellers. NR's status is more settled. This does not change the science, but it explains why availability and labeling around NMN can be inconsistent, and it is a reminder that "widely sold online" is not the same as "fully regulated."
So what should you do in 2026?
Treat NMN and NR as a well-tolerated experiment with promising but unproven benefits — not as a longevity drug. The honest summary: they reliably raise NAD+ in humans, they appear safe in the doses and durations studied so far, and they show scattered early hints of benefit (endurance, blood pressure, insulin sensitivity in one specific group) alongside several solid trials that found no effect. No human study has demonstrated that they slow aging or extend lifespan, and the trials run weeks to months — far too short to answer that question.
If you decide to try one, the human-trial doses cluster around 250–600 mg per day for NMN and around 300–1000 mg for NR; choose a product verified by an independent third-party lab, because supplement quality control varies widely. Talk to your doctor first, especially if you take other medications. And keep the proportion right: across all of this research, the interventions with the strongest evidence for healthy aging remain the unglamorous ones — sleep, regular movement and a good diet do far more for you than any NAD+ capsule. If you want to understand the deeper biology of why your NAD+ falls in the first place, our NAD+ and aging explainer covers the cellular mechanism in plain language.
Common questions
Does NMN really work?
NMN reliably raises NAD+ in human blood, which is confirmed in randomized trials. Beyond that, the downstream benefits are early and mixed: some trials found small gains in walking distance, blood pressure or insulin sensitivity, while several well-run trials found nothing. No human trial has shown NMN slows aging or extends lifespan.
Is NMN safe to take?
Across the human trials done so far, both NMN and NR appear safe and well tolerated at the doses and durations studied. A rigorous 12-week NR trial in obese men confirmed safety even while finding no benefit to insulin sensitivity. Still, the trials run only weeks to months, so longer-term safety remains unproven.
How much NMN should you take?
In human trials, NMN doses cluster around 250 to 600 mg per day, and NR around 300 to 1000 mg per day. If you try one, choose a product verified by an independent third-party lab, since supplement quality control varies widely, and talk to your doctor first, especially if you take other medications.